Wolfe Research Upgrades Kymera Therapeutics(KYMR.US) to Buy Rating, Announces Target Price $65
Kymera Therapeutics Analyst Ratings
Buy Rating Affirmed for Longboard Pharmaceuticals Amid Promising Bexicaserin Developments and Strategic Regulatory Advancements
H.C. Wainwright Maintains Longboard Pharmaceuticals(LBPH.US) With Buy Rating, Maintains Target Price $60
Summit Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT) and Arcadia Biosciences (RKDA)
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $16
Perspective Therapeutics Price Target Cut to $27.00/Share From $29.00 by RBC Capital
Perspective Therapeutics Analyst Ratings
RBC Capital Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Cuts Target Price to $27
Stifel Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Raises Target Price to $66
RBC Capital Reaffirms Their Buy Rating on Perspective Therapeutics (CATX)
Dyne Therapeutics Analyst Ratings
AnaptysBio Price Target Raised to $30.00/Share From $20.00 by Truist Securities
Truist Financial Sticks to Its Hold Rating for AnaptysBio (ANAB)
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $16
AnaptysBio Analyst Ratings
Centessa Pharmaceuticals Analyst Ratings
H.C. Wainwright Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $55
AnaptysBio: Strong Buy Rating on Robust Equity Raise and Promising Clinical Pipeline